Navigation Links
John Northcott Joins Lexicon as Vice President of Marketing, Commercial Strategy and Operations

THE WOODLANDS, Texas, June 18, 2013 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced today that John Northcott has joined the company as its vice president of marketing, commercial strategy, and operations. Mr. Northcott brings extensive commercial experience to Lexicon, including both pre-launch planning and on-market commercialization across a variety of therapeutic areas.

Mr. Northcott has held commercial roles in both U.S. and Global marketing for Avastin® with Genentech and the Roche Group, having most recently served as International Business Leader for Avastin, leading global product strategy initiatives in oncology. In addition, Mr. Northcott has experience in a variety of therapeutic areas from previous commercial positions at other pharmaceutical companies including Merck and Pfizer.

In this new position, Mr. Northcott will develop the commercial functions for Lexicon and lead the commercialization of Lexicon's products, with initial focus on telotristat etiprate for carcinoid syndrome. The creation of the position reflects the progress of the company's drug development pipeline and is part of its plan to commercialize one or more drugs in specialty indications. Lexicon is progressing with enrollment in the pivotal Phase 3 trial of telotristat etiprate in carcinoid syndrome, which has Orphan and Fast Track status from the FDA as well as Orphan status in Europe. In addition, Lexicon is proceeding with preparations for the initiation of Phase 3 clinical trials of LX4211 in type 2 diabetes and is completing the Phase 2 program of LX1033 in irritable bowel syndrome.

"John is a talented commercial leader with extensive, highly-relevant experience," said Dr. Arthur T. Sands, president and chief executive officer of Lexicon. "He will be instrumental in formulating and executing the strategic and operational plans essential to bring Lexicon's innovative products to patients."

About Lexicon
Lexicon is a biopharmaceutical company focused on discovering breakthrough treatments for human disease.  Lexicon currently has multiple programs in clinical development for diabetes, irritable bowel syndrome, carcinoid syndrome and other indications, all of which were discovered by Lexicon's research team.  Lexicon has used its proprietary gene knockout technology to identify more than 100 promising drug targets.  Lexicon has focused drug discovery efforts on these biologically-validated targets to create its extensive pipeline of clinical and preclinical programs.  For additional information about Lexicon and its programs, please visit

Safe Harbor Statement
This press release contains "forward-looking statements," including statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information.  All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon's ability to successfully conduct preclinical and clinical development of its potential drug candidates, advance additional candidates into preclinical and clinical development, obtain necessary regulatory approvals, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements.  Information identifying such important factors is contained under "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2012, as filed with the Securities and Exchange Commission.  Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Dr. Victor KR Matsudo Joins ActiGraph Scientific Advisory Board
2. StemCyte, Inc. Joins Rahal Letterman Lanigan Racing As Associate Sponsor Of No. 16 IndyCar Program For James Jakes Beginning With The 97th Indianapolis 500
3. Industry Leader John Reynders Joins Moderna Therapeutics as Chief Information Officer
4. Dalia Dergham Joins Grace Century FZ LLC International Project Team
5. SPIE Joins in Praise for ‘Huge Step Forward’ for Innovation R&D Enabled by Photonics21 Actions
6. Elissa Guerra Joins Pursuit as VP of Client Solutions
7. Graphene joins the race to redefine the ampere
8. Provia Laboratories, LLC Joins Stoneham Chamber of Commerce in Massachusetts
9. Provonix Joins the Medrio Partner Program
10. Danai Brooks Joins Dyadic International as Chief Operating Officer
11. Eastern Clinical Trials Russia-CEE Joins BIOCOM CRO
Post Your Comments:
(Date:11/25/2015)... , Nov. 25, 2015  Neurocrine Biosciences, Inc. (Nasdaq: ... , President and CEO of Neurocrine Biosciences, will be ... in New York . ... the website approximately 5 minutes prior to the presentation ... of the presentation will be available on the website ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... uBiome, were featured on AngelList early in their initial angel funding process. Now, ... syndicate for individuals looking to make early stage investments in the microbiome space. ...
(Date:11/24/2015)... , Nov. 24, 2015 /CNW/ - iCo Therapeutics ("iCo" ... reported financial results for the quarter ended September ... in Canadian dollars and presented under International Financial ... States ," said Andrew Rae , ... regarding iCo-008 are not only value enriching for ...
(Date:11/24/2015)... -- --> --> ... Market by Product & Services (Primer, Probe, Custom Oligos, ... End-User (Research, Pharmaceutical & Biotech, Diagnostic Labs) - Global ... expected to reach USD 1,918.6 Million by 2020 from ... 10.1% during the forecast period. Browse 183 ...
Breaking Biology Technology:
(Date:11/18/2015)... New York , November 18, 2015 ... Market Research has published a new market report titled ... Growth, Trends, and Forecast, 2015 - 2021. According to the ... in 2014 and is anticipated to reach US$29.1 bn ... to 2021. North America ...
(Date:11/17/2015)... 17, 2015 Paris ... --> Paris , qui s,est ... DERMALOG, le leader de l,innovation biométrique, a inventé le ... et empreintes sur la même surface de balayage. Jusqu,ici, ... l,autre pour les empreintes digitales. Désormais, un seul scanner ...
(Date:11/17/2015)... Mass. , Nov. 17, 2015 Pressure ... leader in the development and sale of broadly enabling, ... worldwide life sciences industry, today announced it has received ... its $5 million Private Placement (the "Offering"), increasing the ... $4,025,000.  One or more additional closings are expected in ...
Breaking Biology News(10 mins):